Department of Neurology, Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, PR China.
J Neuroimmunol. 2012 Sep 15;250(1-2):9-17. doi: 10.1016/j.jneuroim.2012.05.008. Epub 2012 Jun 5.
Combination therapies are gaining momentum over monotherapies in the treatment of multiple sclerosis (MS). Suboptimal doses of atorvastatin and rapamycin prevented or reversed clinical and histologic experimental autoimmune encephalomyelitis (EAE). Secretion of proinflammatory Th1 and Th17 cytokines was reduced and Th2 and Treg cytokine secretion was increased in mice. Combination therapy promoted induction of Treg cells and attenuated the infiltration of inflammatory IL-17 cells in EAE. It appeared that rapamycin-reactivated ERK was blunted by addition of atorvastatin. Our results demonstrate that agents with different mechanisms of immune modulation can combine synergistically in treating CNS autoimmunity.
联合治疗在多发性硬化症（MS）的治疗中比单药治疗更有优势。阿托伐他汀和雷帕霉素的低剂量可以预防或逆转临床和组织学实验性自身免疫性脑脊髓炎（EAE）。在小鼠中，促炎 Th1 和 Th17 细胞因子的分泌减少，而 Th2 和 Treg 细胞因子的分泌增加。联合治疗促进了 Treg 细胞的诱导，并减弱了 EAE 中炎症性 IL-17 细胞的浸润。阿托伐他汀的加入似乎使雷帕霉素重新激活的 ERK 受到抑制。我们的结果表明，具有不同免疫调节机制的药物可以在治疗中枢神经系统自身免疫中协同作用。
